

Use of Probiotics in Managing Gastrointestinal Disorders

Muhammad Tanweer Alam¹, Muhammad Usman Alam²

¹ Forensic Pharmacy and Regulatory Academy, Karachi, Pakistan.

² Faculty of Pharmacy and Pharmaceutical Sciences, University of Karachi.

Corresponding Author: forensicpharm.regacademy@gmail.com

Abstract

The global burden of gastrointestinal (GI) disorders is staggering; irritable bowel syndrome (IBS), Inflammatory Bowel Disease (IBD), and gastroenteritis are some of the conditions affecting millions worldwide. Those disorders factor in the suffering of the patients and result in poor quality of life. Probiotics have recently come to the fore, in conditions such as this, as a prospective therapeutic solution. The aim is to look into the role of probiotics in GI disorders, especially concerning their relationships with gut microbiota, immune modulation, and gut-brain axis influence. Probiotics appear to relieve some symptoms of IBS, initiate repair mechanisms against inflammatory challenges in IBD, and prevent antibiotic-associated diarrhea. Many questions remain to be answered, especially with strain-specificity, issues regarding probiotic licenses, and the need for more proper clinical studies. Nevertheless, probiotics offer a useful adjunct to managing GI disorders and represent an acceptable and safe option for their treatment. This paper concludes with a need for further studies to examine their use in optimizing strain-specific effects and their clinical application limitations.

Keywords: Inflammatory Bowel Disease, irritable bowel syndrome, Probiotics

Introduction

Gastrointestinal (GI) disorders constitute a substantial global health problem predominantly affecting millions starkly across conditions like irritable bowel syndrome (IBS), Inflammatory Bowel Disease (IBD), and infections of the gut. They affect not only the physical health of these individuals but also contribute to reduced quality of life, increased healthcare costs, and socio-economic burdens ([Cleveland Clinic, 2021](#)). The past years have witnessed an alarming trend in recent decades toward an increasing prevalence of these disorders requiring entirely new therapeutic options especially among the pediatric and adult populations. Among their other uses, probiotics-preparations of live microorganisms which confer a health benefit upon the host when given in sufficient quantity-will be discussed in one respect for gut health purposes. Such microorganisms include strains of Lactobacillus and Bifidobacterium, which are believed to aid in the restoration of microbial balance, modulation of immune responses, and amelioration of symptoms of various GI conditions. Probiotics already play an important role in medicine today as the benefits of their use for GI conditions continue to expand further in both pediatric and adult wards ([National Institutes of Health, 2023](#)). The evidence from clinical trials taking probiotics for IBS and IBD shows promise. The intent of this research is to review the therapeutic use of probiotics in GI disorders and examine underlying mechanisms, efficacy, and clinical relevance.

Recognizing Gastrointestinal Disorders

One of the types of diseases in medicine is gastrointestinal (GI) disorders. A variety of symptoms will act in varying degrees, affecting an individual's quality of life. Some of the most common GI disorders are IBS (irritable bowel syndrome), IBD (Inflammatory Bowel Disease), and gastroenteritis ([Saha, 2014](#)). The person suffering from IBS usually has abdominal pain and distension, with altered bowel habits affecting a significant portion of the global population, resulting in such individual cases being chronic pain and disability. It means chronic GI tract inflammation and affects people suffering from severe, chilling diseases like diarrhea, weight loss, fever, and fatigue. Gastroenteritis is due to viral or bacterial infection and adds the stomach and intestines with the following symptoms: diarrhea, vomiting, and abdominal pain ([Patel and Shackelford, 2022](#)).

Imbalance in the gut microbiota—a condition known synonymously with gut dysbiosis—and microbial disturbances regularly underlie most gastrointestinal disorders by disrupting the normal digestive function. Overgrowth of pathogenic bacteria, decreased microbial diversity, and loss of gut barrier function all contribute to more severe inflammatory responses in diseases such as IBS and IBD conditions that follow. Like genetic and environmental factors, nutrition-related factors affect ubiquitous growth and development in these diseases ([Hrncir, 2022](#)). Current pharmacological-based strategies mainly include anti-inflammatory drugs, immunosuppressants, and antibiotics as the major types of treatment sought for GI disorders. However, such treatments have been dismal, with significant side effects, short-lived effectiveness, and disease relapse. This renewed attention on new avenues of treatment, such as probiotics, is one of the promising breakthroughs by being minimally invasive in restoring microbial balance and alleviating GI symptoms ([Triantafillidis, 2011](#)).

Probiotics: What Are They?

Probiotics are live microorganisms that confer health benefits to the host when administered adequately, particularly through the modulation of gut microbiota. The strains of *Lactobacillus* and *Bifidobacterium* are elucidated ([Plaza-Diaz et al., 2019](#)). Probiotics are becoming popular because of their nature to maintain and restore gut health. Probiotics provide equilibrium in the gut microbiome, which is important for digestion, immune function, and health ([Fijan, 2014](#)). Probiotic action is complex in the gastrointestinal tract. It covers probiotics attaching to the intestinal mucosa, competing with the pathogenic bacteria for space and nutrients after ingestion. The competition prevents overgrowth from happening in harmful microorganisms. This is attributed to the fact that probiotics promote an increase in mucus and tight junction protein formation, which enhances intestinal barrier function and protects the gut lining from inflammatory and pathogenic agents ([Latif et al., 2023](#)).

On the other hand, probiotics act on the gastrointestinal-associated lymphoid tissue (GALT) to modulate the immune system responses that could help reduce inflammation and augment immune responses. Strain-specific probiotics have different advantages, as their effects often differ because of species and strain-specific properties. For example, cases of IBS symptoms have been studied with *Lactobacillus* strains, while some strains of *Bifidobacterium* could be beneficial in certain inflammatory conditions such as IBD ([Mazziotta et al., 2023](#)). Some fermented food sources include yogurt, kefir, and kimchi, while supplements can be reported as dietary supplements in capsule or powder forms. This is a very convenient way to introduce probiotics into the diet to support gut health.

Role of Probiotics in Gastrointestinal Health

Probiotics are very important in keeping the GI tract healthy, as they interact with gut microbiota and modulate the immune system's responses. Probiotics colonize the gastrointestinal tract after ingestion and establish themselves within the gastrointestinal tract, where they will act together with the host colonized microbiome to maintain a healthy ecosystem's balance ([Hemarajata and Versalovic, 2012](#)). They compete for space and nutrients with harmful pathogens and thus prevent pathogenic overgrowth and dysbiosis, a condition whereby there is a disturbance in the proper balance of microorganisms. They also help maintain the integrity of the gut barrier through the induction of mucus production and strengthen tight junctions between epithelial cells. Marine environments harbor microorganisms and toxins that threaten to destroy the intestinal lining ([Belkaid and Hand, 2014](#)).

On the other hand, immune modulation by probiotics can serve as another dimension in which they play a role in gut health. By influencing the relevant immune cell functions through GALT in the intestine, probiotics can effectively promote anti-inflammatory responses and limit hyperactivation of the immune system, which can result in gastrointestinal disorders such as IBD and IBS ([Wang, Zhang and Zhang, 2021](#)). Moreover, when the production of immunoglobulin secretory IgA is boosted, probiotics are reported to augment the mucosal immunity of the host. This immunoglobulin is important in defense against mucous membranes. Probiotics offer the best promise regarding their possible involvement in the gut-brain axis, the two-way communication street between the bowel and central nervous systems. Improving the gut-brain axis may be of general therapeutic assistance for both digestive diseases and psychological disorders, affecting the mental and digestive well-being of a person through the gut-brain-microbiota interaction ([Oana-Alina Petrariu et al., 2024](#)).

Probiotics for Selected Gastrointestinal Disorders

The use of probiotics in the treatment of various well-defined gastrointestinal disorders, namely, What the patient should be made aware of is IBS, IBD, and antibiotic-induced diarrhea. The therapeutic effects of probiotics in these specific digestive disorders have, therefore, undergone considerable scientific study, and their role in gut healing is becoming increasingly evident ([Satish Kumar et al., 2022](#)). Irritable Bowel Syndrome (IBS) a psychological, gastrointestinal disorder of the functional variety, is characterized by such symptoms as abdominal pain, bloating, and altered bowel habits. These disturbances severely compromise the quality of life of individuals afflicted with this ailment ([Lehrer, 2019](#)). Probiotics have been shown to ameliorate the symptoms of IBS, especially Lactobacillus and Bifidobacterium Strains, by restoring the microbial balance and alleviating inflammation in the gut. It has also been shown that probiotics act in the regulation of motility, relieve bloating, and enhance gut barrier function, thus working towards symptom resolution in IBS patients. Adequate clinical trials have been conducted to provide evidence for the use of certain probiotics in IBS management, with the majority of patients reporting an amelioration of symptoms and gastrointestinal function ([Benjak Horvat et al., 2021](#)).

IBD encompasses all cases of Crohn's disease and ulcerative colitis, characterized by chronic inflammation with resultant symptoms of diarrhea, weight loss, and excruciating pain in the abdomen. In the case of IBD, probiotics have been shown to assist in the reduction of intestinal inflammation, healing of the gut lining, and modulation of immune response. Lactobacillus rhamnosus and Saccharomyces boulardii strains can induce and keep remission in IBD, thereby minimizing exacerbation and relapsing episodes of the disease ([McDowell, Farooq and Haseeb, 2023](#)). The current evidence suggests that probiotics may also be used as an adjunct to conventional therapies, thereby enhancing their clinical efficacy and reducing the need for immunosuppressive drug therapy Antibiotic-associated diarrhea is one of the very common

complications precipitated by antibiotic therapy, which usually happens as a result of gut microbiota interference. Probiotics have been studied widely in prevention and therapy of antibiotic-associated diarrhea by reinstating the depleted gut microbiota and inhibiting the overgrowth of pathogenic bacteria such as *Clostridium difficile* ([Goodman et al., 2021](#)). Probiotics can also be useful in the treatment of infectious gastroenteritis caused by either viruses or bacteria through modulating gut immune response and maintaining intact intestinal barrier integrity. Clinical trials have shown that probiotics shorten the duration and lessen the severity of diarrhea, making them a potentially effective means to combat these two very common gastrointestinal problems ([Britton and Versalovic, 2008](#)).

Benefits and Challenges of Using Probiotics

Probiotics confer several benefits, which render them appealing for the management of gastrointestinal (GI) disorders. One of the major benefits of probiotics is their safety profile. They are considered to be safe for the vast majority of people with very few side effects, which makes these a credible option for long-term use in both adult and child subjects. A favorable attribute is that the use of probiotics does not require any specific intervention because they are widely available in the form of fermented foods and other dietary supplements ([Das et al., 2022](#)).

Nevertheless, a number of challenges do exist in the use of probiotics. A significant issue is the relative ineffectiveness of specific probiotic strains. Different strains engender different therapeutic efficacies, an effect that might also depend largely on the preexisting gut microbiota of the recipients. The next big hurdle, however, is faced on the regulatory front. The lack of standardized, accepted guidelines regarding the formulation, dosing, and quality control of probiotic supplements creates a vacuum with respect to these products ([Hmar, Paul and Sharma, 2024](#)). While probiotics are promising, it remains to be established through more convincing clinical trials just what the long-term benefits are and which strains are most warranted for specific GI disorders. Future research is needed to investigate all possible areas for the application of probiotics concerning GI health. Future studies should investigate strain-specific effects, ideal dosages, and long-term outcomes across a range of populations, refining the applications of probiotic therapy for clinical settings ([Sarita et al., 2025](#)).

Strain-Specific Effects and Mechanisms

Different therapeutic results occur throughout probiotic strains, even when they belong to one identical species. Officials have discovered that *Lactobacillus rhamnosus* succeeds in treating diarrhoea, yet *Bifidobacterium longum* offers aid to individuals dealing with IBS symptoms. Probiotic effects vary because each strain demonstrates distinct biochemical traits that control how they work with gut bacteria and impact immune system regulation and gut wall integrity ([Lau and Quek, 2024](#)). Different probiotic strains demonstrate specific advantages for various gastrointestinal diseases because they actively target particular infection-causing bacteria and inflammatory processes. Personalized medicine is essential for improving probiotic treatment outcomes because each person responds differently to probiotics that depend on their genetics, gut microbiota structure, and medical needs. Treatment success and GI disorder management will improve considerably when probiotic applications align with a patient's unique requirements and microbial makeup ([Maftei et al., 2024](#)).

Regulatory Aspects and Quality Control

The regulation of probiotics becomes complex because various regions fail to establish common procedural standards. Probiotics usually receive food supplement classification instead of pharmaceutical drug status because of different regulatory criteria. Product quality standards and potency levels become difficult to maintain because of missing regulatory guidelines. Probiotic

products lack a standardized framework to evaluate their precise composition, necessary microorganism levels, and dosage amounts, so product variations occur between different brands and batches ([Spacova et al., 2023](#)). The effectiveness of probiotics varies because their effectiveness depends on the product's strain selection and storage conditions. The absence of proper regulations makes it difficult for consumers to select suitable probiotics which match their requirements. Various organizations work toward developing stricter regulatory standards that will help determine strains alongside proper dosage amounts and product identification requirements ([Fenster et al., 2019](#)). The safety standards increased quality, and consistent outcomes from these measures benefit consumers who require dependable probiotic treatment solutions.

Conclusion

To summarize, probiotics could be a promising option for the treatment of a variety of GI disorders, including the following: IBS, IBD, and gastroenteritis. Reinstating the microbial balance, improving gut barrier function, and modulating immune responses are examples of therapeutic benefits that would justify the consideration of probiotics as adjunct therapies in traditional pharmacological treatment. Probiotics most promisingly have proved to be effective in simulating the remission of IBD, relief of IBS symptoms, as well as in preventing AAD, offering an alternative for a safer, cheaper source. However, much research is required to overcome issues of strain variability, regulatory standards, and the need for better clinical evidence, as well as many directions that probiotics can take in integrated patient practice to support patients diagnosed with chronic and acute GI conditions. Emerging studies should aim at establishing optimal probiotic use in various populations, whereby these interventions could be personalized to the patient and his/her condition.

References

- Belkaid, Y. and Hand, Timothy W. (2014). Role of the Microbiota in Immunity and Inflammation. *Cell*, 157(1), pp.121–141. <https://doi.org/10.1016/j.cell.2014.03.011>.
- Benjak Horvat, I., Gobin, I., Kresović, A. and Hauser, G. (2021). How can probiotic improve irritable bowel syndrome symptoms? *World Journal of Gastrointestinal Surgery*, 13(9), pp.923–940. <https://doi.org/10.4240/wjgs.v13.i9.923>.
- Britton, R.A. and Versalovic, J. (2008). Probiotics and Gastrointestinal Infections. *Interdisciplinary Perspectives on Infectious Diseases*, [online] 2008. <https://doi.org/10.1155/2008/290769>.
- Cleveland Clinic (2021). Gastrointestinal Diseases: Symptoms, Treatment & Causes. [online] Cleveland Clinic. Available at: <https://my.clevelandclinic.org/health/articles/7040-gastrointestinal-diseases>.
- Das, T.K., Pradhan, S., Chakrabarti, S., Mondal, K.C. and Ghosh, K. (2022). Current status of probiotic and related health benefits. *Applied Food Research*, [online] 2(2), p.100185. <https://doi.org/10.1016/j.afres.2022.100185>.
- Fenster, K., Freeburg, B., Hollard, C., Wong, C., Rønhave Laursen, R. and Ouwehand, A. (2019). The Production and Delivery of Probiotics: A Review of a Practical Approach. *Microorganisms*, 7(3), p.83. <https://doi.org/10.3390/microorganisms7030083>.
- Fijan, S. (2014). Microorganisms with Claimed Probiotic Properties: An Overview of Recent Literature. *International Journal of Environmental Research and Public Health*, 11(5), pp.4745–4767. <https://doi.org/10.3390/ijerph110504745>.
- Goodman, C., Keating, G., Georgousopoulou, E., Hespe, C. and Levett, K. (2021). Probiotics for the prevention of antibiotic-associated diarrhoea: a systematic review and meta-analysis. *BMJ Open*, 11(8), p.e043054. <https://doi.org/10.1136/bmjopen-2020-043054>.

- Hemarajata, P. and Versalovic, J. (2012). Effects of probiotics on gut microbiota: mechanisms of intestinal immunomodulation and neuromodulation. *Therapeutic Advances in Gastroenterology*, 6(1), pp.39–51. <https://doi.org/10.1177/1756283x12459294>.
- Hmar, E.B.L., Paul, S. and Sharma, H.K. (2024). An Insight into the Combination of Probiotics and their Implications for Human Health. *Endocrine, metabolic & immune disorders drug targets*, [online] 24(1), pp.1–12. <https://doi.org/10.2174/1871530323666230502141717>.
- Hrncir, T. (2022). Gut Microbiota Dysbiosis: Triggers, Consequences, Diagnostic and Therapeutic Options. *Microorganisms*, 10(3), p.578. <https://doi.org/10.3390/microorganisms10030578>.
- Latif, A., Aamir Shehzad, Niazi, S., Zahid, A., Ashraf, W., Muhammad Waheed Iqbal, Rehman, A., Riaz, T., Rana Muhammad Aadil, Khan, I., Fatih Özogul, João Miguel Rocha, Tuba Esatbeyoglu and Korma, S.A. (2023). Probiotics: Mechanism of action, Health Benefits and Their Application in Food Industries. *Frontiers in Microbiology*, 14(14). <https://doi.org/10.3389/fmicb.2023.1216674>.
- Lau, L.Y.J. and Quek, S.Y. (2024). Probiotics: Health benefits, food application, and colonization in the human gastrointestinal tract. *Food Bioengineering*, [online] 3(1), pp.41–64 <https://doi.org/10.1002/fbe2.12078>.
- Lehrer, J. (2019). Irritable Bowel Syndrome (IBS): Practice Essentials, Background, Pathophysiology. [online] Medscape.com. Available at: <https://emedicine.medscape.com/article/180389-overview>.
- Maftai, N.-M., Raileanu, C.R., Balta, A.A., Ambrose, L., Boev, M., Marin, D.B. and Lisa, E.L. (2024). The Potential Impact of Probiotics on Human Health: An Update on Their Health-Promoting Properties. *Microorganisms*, [online] 12(2), p.234. <https://doi.org/10.3390/microorganisms12020234>.
- Mazziotta, C., Tognon, M., Martini, F., Torreggiani, E. and Rotondo, J.C. (2023). Probiotics mechanism of action on immune cells and beneficial effects on human health. *Cells*, [online] 12(1), p.184. <https://doi.org/10.3390/cells12010184>.
- McDowell, C., Farooq, U. and Haseeb, M. (2023). Inflammatory Bowel Disease (IBD). [online] PubMed. Available at: <https://www.ncbi.nlm.nih.gov/books/NBK470312/>.
- National Institutes of Health (2023). Probiotics. [online] Nih.gov. Available at: <https://ods.od.nih.gov/factsheets/Probiotics-HealthProfessional/>.
- Oana-Alina Petrariu, Ilda Czobor Barbu, Niculescu, A.-G., Constantin, M., Georgiana Alexandra Grigore, Cristian, R.-E., Grigore Mihaescu and Corneliu Ovidiu Vrancianu (2024). Role of probiotics in managing various human diseases, from oral pathology to cancer and gastrointestinal diseases. *Frontiers in Microbiology*, 14. <https://doi.org/10.3389/fmicb.2023.1296447>.
- Patel, N. and Shackelford, K. (2022). Irritable Bowel Syndrome. [online] PubMed. Available at: <https://www.ncbi.nlm.nih.gov/books/NBK534810/>.
- Plaza-Diaz, J., Ruiz-Ojeda, F.J., Gil-Campos, M. and Gil, A. (2019). Mechanisms of Action of Probiotics. *Advances in Nutrition*, [online] 10(1), pp.S49–S66. <https://doi.org/10.1093/advances/nmy063>.
- Saha, L. (2014). Irritable bowel syndrome: Pathogenesis, diagnosis, treatment, and evidence-based medicine. *World Journal of Gastroenterology*, 20(22), pp.6759–6773. <https://doi.org/10.3748/wjg.v20.i22.6759>.
- Sarita, B., Dahikar Samadhan, Hassan, M.Z. and Kovaleva, E.G. (2025). A comprehensive review of probiotics and human health-current prospective and applications. *Frontiers in Microbiology*, 15. <https://doi.org/10.3389/fmicb.2024.1487641>.

- Satish Kumar, L., Pugalenti, L.S., Ahmad, M., Reddy, S., Barkhane, Z. and Elmadi, J. (2022). Probiotics in Irritable Bowel Syndrome: a Review of Their Therapeutic Role. *Cureus*, 14(4). <https://doi.org/10.7759/cureus.24240>.
- Spacova, I., Binda, S., Jessica, Henoud, S., Legrain–Raspaud, S., Dekker, J., Jordi Espadaler-Mazo, Langella, P., Martín, R., Pane, M. and Ouwehand, A.C. (2023). Comparing technology and regulatory landscape of probiotics as food, dietary supplements and live biotherapeutics. *Frontiers in Microbiology*, [online] 14. <https://doi.org/10.3389/fmicb.2023.1272754>.
- Triantafyllidis, J. (2011). Current and emerging drugs for the treatment of inflammatory bowel disease. *Drug Design, Development and Therapy*, p.185. <https://doi.org/10.2147/dddt.s11290>.
- Wang, X., Zhang, P. and Zhang, X. (2021). Probiotics Regulate Gut Microbiota: An Effective Method to Improve Immunity. *Molecules*, [online] 26(19), p.6076. <https://doi.org/10.3390/molecules26196076>.